Abstract Title:

Preclinical studies on antineoplaston AS2-1 and antineoplaston AS2-5.

Abstract Source:

Drugs Exp Clin Res. 1986 ;12 Suppl 1:11-6. PMID: 3743376

Abstract Author(s):

S R Burzynski, M O Mohabbat, S S Lee


Antineoplaston AS2-1 and Antineoplaston AS2-5 are degradation products of Antineoplaston A10. The initial hydrolysis of Antineoplaston A10 (3-phenylacetylamine-2, 6-piperidinedione) yields phenylacetylglutamine and phenylacetylisoglutamine. When hydrolysis is carried further the products of the reaction include phenylacetic acid, glutamic acid and ammonia. Sodium salts of phenylacetylglutamine, named Antineoplaston AS2-5, phenylacetic acid and a mixture of phenylacetylglutamine and phenylacetic acid in the ratio of 1:4, named Antineoplaston AS2-1, were submitted for tissue culture and animal toxicity studies. Tissue culture tests were carried out on breast carcinoma cell lines HBL-100 and Ki No. 1 and the results were expressed as the percentage of colony reduction based on control. Acute toxicity studies were done on a group of 88 HA/ICR Swiss mice with each of these formulations. An additional group of 160 mice was used for chronic toxicity studies of Antineoplaston AS2-1. In chronic toxicity studies the mice were injected with 92.3 mg/kg, 553.8 mg/kg and 1107.6 mg/kg of Antineoplaston AS2-1 intraperitoneally for 365 days and subjected to complete physical, gross pathology and microscopic examination. LD50 for tested formulations were as follows: Antineoplaston AS2-1: 2.83 g/kg, Antineoplaston AS2-5: 2.90 g/kg and phenylacetic acid: 2.71 g/kg. The results clearly demonstrated that Antineoplaston AS2-1 has interesting antineoplastic activity in tissue culture of breast carcinoma, and low acute and chronic toxicity in mice. Antineoplaston AS2-5 does not show significant activity in tissue culture of breast carcinoma HBL-100 and only slight antineoplastic activity in Ki No. 1. Both formulations were submitted for phase I clinical testing in cancer patients.

Print Options

Sayer Ji
Founder of GreenMedInfo.com

Subscribe to our informative Newsletter & get Nature's Evidence-Based Pharmacy

Our newsletter serves 500,000 with essential news, research & healthy tips, daily.

Download Now

500+ pages of Natural Medicine Alternatives and Information.

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2022 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.